Retatrutide is a novel investigational peptide developed by Eli Lilly that targets three key receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
Recent years have seen a number of new drugs become available for the management of type 2 diabetes, and emerging evidence suggests that many of these agents have benefits beyond their effects on blood glucose control
For TB-500, the situation is similar or thinner, with much of the strongest science attached to the parent protein Thymosin Beta-4 rather than the marketed fragment
References Christensen, S., Robinson, K., Thomas, S., et al
Early- to mid-stage trials in people with obesity (with and without type 2 diabetes) have reported substantial average weight reductions over 48 weeks at higher doses, alongside improvements in measures like waist circumference, blood lipids and liver fat in those with metabolic fatty liver disease